|
Sign In to gain access to subscriptions and/or personal tools.
|
An Update in the Management of Hepatitis B/HIV Coinfection
Monika N. Daftary, PharmD
Howard University School of Pharmacy, 2300 4th Street, NW, Washington, DC 20059; mdaftary{at}howard.edu
Tiffany Goolsby, PharmD
Faria Farhat, MD
With growing numbers of hepatitis B virus (HBV)/ HIVcoinfected patients and the complexity of treating both diseases together, new treatment options and guidelines are available. This article reviews treatment and management options for HBV/HIV-coinfected patients.
Key Words: HIV • hepatitis B • coinfection • treatment
References
Soriano V, Massimo P, Maurizio B, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19:221-240.[Web of Science][Medline]
[Order article via Infotrieve] Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis. 2005;5:374-382.[CrossRef][Medline]
[Order article via Infotrieve]Konopnicki D, Mocroft A, deWit S, et al; Euro SIDAGroup. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro SIDA cohort. AIDS. 2005;19:593-601.[Web of Science][Medline]
[Order article via Infotrieve]New drug: Baraclude (entecavir). Pharmacist's Letter/ Prescriber's Letter. 2005;21:210-210Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857-861.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039-2045.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. April 07, 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/archive/AA_040705.pdf.US Food and Drug Administration. Pegasys [prescribing information. Available at: http://www.fda.gov/cder/foi/label/2005/103964s5037lbl.pdf. Accessed July 5, 2005.Hayden FG. Antiviral agents (nontretroviral). In: Hardman JG, Limbird LE, Goodman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:1332-1336.Thio CL. Management of chronic hepatitis B in the HIV-infected patient. AIDS Read. 2004;14:122-129, 133-133, 136-137.Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347-356.[Free Full Text]Wong DK, Cheung AM, O'Rourke K, Naylor D, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patientswith hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1993;119:312-323.[Abstract/Free Full Text]Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. NEngl JMed. 1990;323:295-301.[Abstract]Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123:1812-1822.[CrossRef][Web of Science]Lau GK, Luo KX, Marcellin P, et al. Peginterferon alfa-2a, lamivudine, and thhepatitis B. N Engl J Med. 2005;352:2682-2695.[Abstract/Free Full Text]Marcellin P, Lau GK, Bonino F, et al.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBe Ag-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-1217.[Abstract/Free Full Text]Cooksley WG. Peginterferon-alpha(2a) for the treatment of hepatitis Binfection. Expert Opin Pharmacother. 2005;6:1373-1380.[Medline]
[Order article via Infotrieve]AIDSinfo. Available at: www.aidsinfo.nih.gov. Accessed July 6, 2005.Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis. 1999;180:607-613.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis. 2001;32:963-969.[CrossRef][Medline]
[Order article via Infotrieve]Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302-1306.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs. 2005;65:1427-1448.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. Hepatology. 2005;43:60-66.[CrossRef]Hepsera (adefovir dipivoxil) [package insert]. Foster City, Calif: Gilead Sciences; 2004.Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis Band hepatitis Cin HIV co-infected patients. JHepatol. 2005;42:615-624.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Gelinck LB, Claas EC, Kroon FP. The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients. J Hepatol. 2005;43:360-361.[Medline]
[Order article via Infotrieve]Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.[Abstract/Free Full Text]Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.[Abstract/Free Full Text]Benhamou Y, Thiabault V, Vig P. Long-term with adefovir dipivoxil 10 mg in patients with lamivudine-resistant HBV and HIV co-infection results in significant and sustained clinical improvement. Abstract presented at: 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrA1329.Dore G, Cooper D, Pozniak A, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185-1192.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Van Bommel F, Wunscher T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002;36:507-508.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]Baraclude (entecavir) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2005.Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepatol. 2005;12:333-345.[CrossRef][Medline]
[Order article via Infotrieve]HIV and Hepatitis.com. Hepatitis B articles. Available at: http://www.hivandhepatitis.com/hep_b/news.html. Accessed July 29, 2005.Han SH. Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005;14:511-519.[Medline]
[Order article via Infotrieve]
Journal of Pharmacy Practice, Vol. 19, No. 1,
31-36 (2006)
DOI: 10.1177/0897190005284097
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
